This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yen, M. J. Articles by Shih, I.-M. Search for Related Content PubMed PubMed Citation Articles by Yen, M. J. Articles by Shih, I.-M.

Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma

Authors' Affiliations: ¹ Departments of Pathology and Oncology and Gynecology/Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland and ² Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, and Pathology, National Yang-Ming University School of Medicine, Taipei, Taiwan

Requests for reprints: Ie-Ming Shih, Department of Pathology, The Johns Hopkins Medical Institutions, 1503 East Jefferson Street, Room B-315, Baltimore, MD 21231. Phone: 410-502-7773; Fax: 410-502-7943; E-mail: ishih{at}jhmi.edu.

Purpose: Mesothelin is an emerging marker for cancer diagnosis and target-based therapy, yet relatively little is known about the clinical significance of mesothelin expression in tumors. In this study, we correlate mesothelin immunoreactivity to clinicopathologic features in ovarian serous carcinoma.

Experimental Design: Mesothelin expression levels were compared among 81 publicly available serial analysis of gene expression (SAGE) libraries of various carcinoma and normal tissue types. Immunohistochemistry using a well-characterized mesothelin monoclonal antibody (5B2) was done to evaluate mesothelin expression in 167 high-grade and 31 low-grade ovarian serous carcinomas. Immunohistochemistry staining scores were correlated with patient survival, tumor site, tumor grade, in vitro drug resistance, and differentiation status of tumor cells.

Results: SAGE analysis showed that mesothelin was overexpressed in 50% of ovarian and pancreatic carcinomas but rarely in other cancer types, including liver, colon, kidney, prostate, and breast. Mesothelin immunoreactivity (>5% of tumor cells) was present in 55% of ovarian serous carcinomas with no difference in expression between high-grade and low-grade serous tumors (P = 0.82). Based on Kaplan-Meier analysis, we found that a diffuse mesothelin staining (>50% of tumor cells) in primary high-grade ovarian carcinomas correlated significantly with prolonged survival in patients who had advanced-stage disease and had received optimal debulking surgery followed by chemotherapy (P = 0.023). Mesothelin expression did not correlate significantly with patient age, tumor site, in vitro drug resistance, or tumor differentiation status (P > 0.10).

Conclusion: Our results provided new evidence that mesothelin expression is associated with prolonged survival in patients with high-grade ovarian serous carcinoma.

This article has been cited by other articles:

				J. Song, I.-m. Shih, R. Salani, D. W. Chan, and Z. Zhang Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients Clin. Cancer Res., November 15, 2007; 13(22): 6842 - 6849. [Abstract] [Full Text] [PDF]

				M. Ho, T. K. Bera, M. C. Willingham, M. Onda, R. Hassan, D. FitzGerald, and I. Pastan Mesothelin Expression in Human Lung Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1571 - 1575. [Abstract] [Full Text] [PDF]

				K. Nakayama, N. Nakayama, B. Davidson, J. J.-C. Sheu, N. Jinawath, A. Santillan, R. Salani, R. E. Bristow, P. J. Morin, R. J. Kurman, et al. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival PNAS, December 5, 2006; 103(49): 18739 - 18744. [Abstract] [Full Text] [PDF]